论文部分内容阅读
目的探讨醒脑静联合依达拉奉治疗急性脑梗死(ACI)早期神经功能恶化的效果。方法 ACI早期神经功能恶化患者80例随机均分为两组,均给予常规综合治疗;对照组加用醒脑静与依达拉奉静脉滴注,疗程为1个月。采用NIHSS评分、Barthel指数(BI)和道格拉斯昏迷评分(GCS)评估疗效。结果治疗后,两组神经功能均有明显改善(P<0.05)。观察组治疗后的GCS评分、NIHSS评分及BI指数分别为(12.83±2.85)分、(12.83±2.85)和(46.92±6.27)分,均明显优于对照组的(11.04±2.64)分、(16.58±3.15)和(38.68±7.23)分(P<0.05)。观察组治疗总有效率明显高于对照组(50.0%vs.22.5%)(P<0.05)。结论对ACI早期神经功能恶化患者,在常规综合治疗基础上加用醒脑静和依达拉奉治疗能明显改善患者神经功能。
Objective To investigate the effect of xingnaojing combined with edaravone in the treatment of early neurological deterioration in acute cerebral infarction (ACI). Methods Eighty patients with early neurological deterioration of ACI were randomly divided into two groups. All patients were given conventional therapy. The control group was treated with intravenous injection of xingnaojing and edaravone, and the course of treatment was 1 month. The NIHSS score, Barthel index (BI) and Douglas coma score (GCS) were used to assess the efficacy. Results After treatment, the neurological function was significantly improved in both groups (P <0.05). The GCS score, NIHSS score and BI index in the observation group were (12.83 ± 2.85), (12.83 ± 2.85) and (46.92 ± 6.27) points respectively, which were significantly better than those in the control group (11.04 ± 2.64), ( 16.58 ± 3.15) and (38.68 ± 7.23) points (P <0.05). The total effective rate of observation group was significantly higher than that of control group (50.0% vs.22.5%) (P <0.05). Conclusions In the early stage of ACI patients with neurological deterioration, the combination of xingnaojing and edaravone can significantly improve the neurological function of patients on the basis of conventional comprehensive treatment.